CCO Oncology Podcast Clinical Care Options

Listen in as Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the CLL guidelines from the NCCN and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes.

Listen to this podcast featuring a multidisciplinary discussion between Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, for expert guidance on optimal biomarker testing to guide treatment decisions in advanced prostate cancer.

Discussion between experts on novel and emerging HER2-targeted and TROP-2–directed therapies for patients with HER2-low, hormone receptor–positive, and triple-negative advanced breast cancer.

In this podcast, Rebecca S. Heist, MD, MPH, discusses the safety profile and management of potential adverse events associated with HER3-directed therapies in lung cancer.

In this podcast, Helena Yu, MD, and Rebecca S. Heist, MD, MPH, discuss ongoing clinical trials of HER3-targeted therapy for patients with advanced NSCLC and how these agents have the potential to change treatment options in this setting.

In this podcast, Helena Yu, MD, discusses recent advances in the field of antibody–drug conjugates and the current rationale for targeting HER3 for treatment of non-small-cell lung cancer.